Navigation Links
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Date:7/29/2009

me period in 2008. GAAP net loss per share for the six months ended June 30, 2009 was $0.56 per share, basic and diluted, compared to a GAAP net income per share of $0.56, basic, and $0.51, diluted, for the same period in 2008.

Non-GAAP adjusted net income in the three and six months ended June 30, 2009 was $34.5 million and $46.0 million, respectively, compared to $28.9 million and $51.0 million, respectively, for the same periods in 2008.

The primary drivers of the GAAP net loss in the six months ended June 30, 2009 was the impairment of goodwill for $65.1 million, offset by the gain on our repurchase of our senior convertible notes of $9.1 million. Contributing to this loss were launch costs for Cinryze, increased expenses relating to the development of our product pipeline, and the increase in amortization expense. GAAP net income decreased for the second quarter of 2009 as compared to 2008 due to a decrease in Vancocin sales, increased SG&A costs related to the launch of Cinryze, increased amortization and lower interest income, partially offset by Cinryze sales.

Effective January 1, 2009, the Company adopted Financial Accounting Standards Board's Staff Position No. APB 14-1, "Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)" ("FSP APB 14-1"), which changed the method of accounting for the Company's convertible notes. The Company revised its previously reported financial statements to apply this change in accounting to prior periods. Under this new accounting method, the Company's EPS and net (loss) income calculated in accordance with GAAP have been reduced as a result of recognizing incremental non-cash interest expense. In connection with adopting FSP APB 14-1, the Company recorded $1.7 million and $2.0 million of additional non-cash interest expense in the three months ended June 30, 2009 and 2008, respectively, and $3
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk decided to ... Recently, the company has unveiled its 2014 vintage ... wedding gowns, Angeldress.co.uk wants to make sure that all ... way. Its high quality vintage wedding outfits are now ... 62% off. , Online shopping is becoming more and ...
(Date:9/21/2014)... September 21, 2014 “Cluster headaches are ... intense and difficult to resolve,” said Steve Young of ... think of a pain that is more intense.” , ... from cluster headaches, or migraines, that medical research is ... serotonin system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is ...
(Date:9/21/2014)... C8 lawsuits move forward in the U.S. ... of 20 possible C8 lawsuits selected for bellwether ... Wright & Schulte LLC. Court records show these six ... lawsuits filed that represent individuals who purportedly developed kidney ... of being exposed to water contaminated by the C8 ...
(Date:9/20/2014)... Recently, UWDress.com, a professional company of women’s dresses ... newly announced evening cocktail dresses . As a ... outfits are very popular among worldwide customers. Now, all ... (up to 65 percent off). , All UWDress.com’s ... occasion outfits for the global clients. The company is ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 David Cooke ... 2014. The first poster looked at the clinical benefits ... cycle for calculating diastolic function. In conjunction with colleagues ... renal disease and normal LVEF by echo (>50%). Each ... protocol, and standard SPECT. Emory Toolbox 4.0 ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Cheap Evening Cocktail Dresses Recently Introduced At UWDress.com 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 2Health News:Versatility of Emory Toolbox 4.0 Shown at ASNC in Scientific Posters 3
... Jenifer Goodwin HealthDay Reporter , MONDAY, Aug. ... marijuana, reduced pain in patients with nerve pain stemming ... Twenty-one adults with chronic nerve pain were taught to ... through a pipe, three times a day, for five ...
... When given a choice, older people prefer to read negative news, ... In fact, older readers who chose to read negative stories ... according to the results. And what about younger people? Well, ... results come from a study of 276 Germans who were asked ...
... growing epidemic of the world,s most common heart rhythm ... admissions in Australia, according to cardiology researchers. A ... University of Adelaide and the Cardiovascular Research Centre at ... to atrial fibrillation had more than tripled in Australia ...
... Children,s Hospital finds visits to emergency departments for concussions ... over a 10-year period, and appear to be highest ... concussions is highest in high school-aged athletes, but the ... study is published in the September 2010 issue of ...
... By Jenifer Goodwin HealthDay Reporter , SUNDAY, ... a gene on chromosome 8 may raise the risk of ... been believed to have a genetic component, pinpointing specific genes ... is among the first to identify a specific genetic variant ...
... who will develop tuberculosis, as scientists have identified changes ... are from an international study published in the August ... doctors and researchers at Nationwide Children,s Hospital using blood ... is caused by the bacterium Mycobacterium tuberculosis, which usually ...
Cached Medicine News:Health News:Smoked Marijuana May Ease Chronic Nerve Pain 2Health News:Smoked Marijuana May Ease Chronic Nerve Pain 3Health News:Over 50? You probably prefer negative stories about young people 2Health News:Over 50? You probably prefer negative stories about young people 3Health News:Heart disorder hits national epidemic proportions 2Health News:Concussions in young athletes on the rise 2Health News:Concussions in young athletes on the rise 3Health News:New Migraine Gene Discovered 2Health News:New Migraine Gene Discovered 3Health News:New genomic marker for tuberculosis may help identify patients who will develop the disease 2Health News:New genomic marker for tuberculosis may help identify patients who will develop the disease 3
(Date:9/19/2014)... CHICAGO, Ill. , Sept. 19, 2014  The ... ABBV ) declared a quarterly cash dividend of $0.42 ... payable Nov. 17, 2014 to stockholders of record at ... About AbbVie AbbVie is a global, research-based biopharmaceutical ... company,s mission is to use its expertise, dedicated people ...
(Date:9/19/2014)... STATION, N.J. , Sept. 19, 2014 Merck (NYSE: ... United States and Canada , is ... Desafiando La Diabetes: Logra Tus Metas , an educational program ... their blood sugar -- a key treatment goal to help reduce ... United States are at a higher risk for developing ...
(Date:9/19/2014)... 2014 Larry J. Merlo , President and ... speak before the National Press Club in Washington, ... move to stop selling tobacco products and its leadership in ... "Dramatic changes in our health care system pose ... Merlo has said. "CVS Health has a truly unique combination ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3
... PASADENA, Calif.--(BUSINESS WIRE)--Jun 20, 2007 - Materia, ... licensing of its,metathesis platform to Eisai Co., ... in drug discovery and development.,The non-exclusive license ... pharmaceutical compounds and related processes,using the Company's ...
... 2007 - VIVUS, Inc.,(NASDAQ: VVUS), a pharmaceutical ... novel therapeutic products,announced that Abstract #2209-PO, Evaluation ... with Phentermine and Topiramate:,Outcomes in a Private ... Diabetes Association 2007 Scientific Sessions Abstract,book. The ...
Cached Medicine Technology:Materia Licenses Metathesis Catalyst Platform to Eisai 2VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions 2VIVUS Announces Abstract Published at American Diabetes Association,Scientific Sessions 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: